Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Matt Posard
AddedMar 31, 2024
UpdatedMay 31, 2026
Matt Posard

Matt Posard

Board Member, Halozyme Therapeutics

CrunchbaseLinkedIn

Matt Posard's Career

Halozyme Therapeutics
Halozyme Therapeutics

San Diego, CA, US

Board Member· Board
SlipChip
SlipChip

Chicago, IL, US

Board Member· Board
Stemson Therapeutics
Stemson Therapeutics

San Diego, CA, US

Board Member· Board
Deepcell
Deepcell

Menlo Park, CA, US

Board Member· Board
Vizgen
Vizgen

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Matt Posard's Career

Halozyme Therapeutics
Halozyme Therapeutics
Public$745M3931998San Diego, CA, US
Board Member· Board

Leadership at Halozyme Therapeutics

Kate FalbergKate FalbergBoard Member
Helen TorleyHelen TorleyBoard Member
Gregory FrostGregory FrostCo-Founder
Barbara DuncanBarbara DuncanBoard Member
John S. PattonJohn S. PattonCo-Founder
KarwishKarwishBoard Member

Similar to Halozyme Therapeutics

ZenomicsZenomicsDurham, NC, USDrug Deliveryest. 2015ZenomicsDurham, NC, US · est. 2015

Zenomics: Innovating diabetes treatment through advanced drug delivery systems.

Seed · $2.8M8
Heron TherapeuticsHeron TherapeuticsSan Diego, CA, USPharmaceuticalsest. 1983Heron TherapeuticsSan Diego, CA, US · est. 1983

Heron Therapeutics: A US-based biotech firm enhancing injectable pharmaceuticals via proprietary drug delivery tech.

Public · $974M203
Denali TherapeuticsDenali TherapeuticsSan Francisco, CA, USBiotechest. 2015Denali TherapeuticsSan Francisco, CA, US · est. 2015

Denali Therapeutics, a US-based biotech firm, develops medicines for neurodegenerative diseases.

Public · $622M427
Gyre TherapeuticsGyre TherapeuticsSan Diego, CA, USBiopharmaceuticalsest. 1997Gyre TherapeuticsSan Diego, CA, US · est. 1997

San Diego-based Gyre Therapeutics develops and commercializes Hydronidone, a leading biopharmaceutical.

Public75
SlipChip
SlipChip
Series B$30.6M302010Chicago, IL, US
Board Member· Board

Leadership at SlipChip

Brian CoeBrian CoeCEO

Similar to SlipChip

Empowered DiagnosticsEmpowered DiagnosticsPompano Beach, FL, USDiagnostic Testsest. 2017Empowered DiagnosticsPompano Beach, FL, US · est. 2017

Empowered Diagnostics: Reliable, affordable, high-quality diagnostic tests for informed health decisions.

Seed · $4.7M13
BioChip LabsBioChip LabsCleveland, OH, USBlood Testingest. 2019BioChip LabsCleveland, OH, US · est. 2019

Biochip Labs, a CLIA-certified lab in Ohio, specializes in blood disorder testing since 2019.

Angel · $406k8
SapphirosSapphirosBoston, MA, USDiagnosticsest. 2021SapphirosBoston, MA, US · est. 2021

Sapphiros: Investing in innovative, patient-centric diagnostic technologies for global accessibility.

Series B · $41M18
Predictive Health Diagnostics CompanyPredictive Health Diagnostics CompanyIrvine, CA, USDiagnostic Testsest. 2017Predictive Health Diagnostics CompanyIrvine, CA, US · est. 2017

Predictive Health Diagnostics: Transforming data into intelligent, science-driven diagnostic tests.

Series A · $17.3M29
Stemson Therapeutics
Stemson Therapeutics
Series A$22.5M362018San Diego, CA, US
Board Member· Board

Leadership at Stemson Therapeutics

Alexey V TerskikhAlexey V TerskikhCo-Founder
Geoff HamiltonGeoff HamiltonCo-Founder
Deepcell
Deepcell
Series B$98M1112017Menlo Park, CA, US
Board Member· Board

Leadership at Deepcell

Mahyar SalekMahyar SalekCo-Founder
Maddison Mahdokht MasaeliMaddison Mahdokht MasaeliCo-Founder
Euan AshleyEuan AshleyCo-Founder

Similar to Deepcell

Sampling HumanSampling HumanBerkeley, CA, USHealthTechest. 2016Sampling HumanBerkeley, CA, US · est. 2016

Sampling Human: Advancing health tech by linking decisions to cellular effects for precise diagnoses.

Seed · $3.7M37
CelldomCelldomDurham, NC, USSingle-Cell Analysisest. 2016CelldomDurham, NC, US · est. 2016

Celldom advances research and drug development with high-throughput, next-gen single-cell analysis technology.

Seed · $1.9M5
CellarityCellaritySomerville, MA, USMedicine Developmentest. 2017CellaritySomerville, MA, US · est. 2017

Cellarity, a Flagship Pioneering company, harnesses machine learning for innovative medicine development.

Series C · $294M165
Drift BioDrift BioSan Francisco, CA, USHealthcare, Softwareest. 2020Drift BioSan Francisco, CA, US · est. 2020

Drift Biotechnologies: Innovating disease software solutions for a healthier future.

Pre-Seed · $500k2
Vizgen
Vizgen
Series C$136.2M952019Cambridge, MA, US
Board Member· Board

Leadership at Vizgen

Marijn DekkersMarijn DekkersBoard Member
Andrea JacksonAndrea JacksonBoard Member
Jeffrey R MoffittJeffrey R MoffittBoard Member
Jiang HeJiang HeCo-Founder
Terry LoTerry LoCEO

Matt Posard's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Matt Posard

David NeighboursDavid NeighboursBoard Member · True Partners ConsultingGene FlemingGene FlemingBoard Member · QualDerm PartnersBradley PattBradley PattBoard Member · HyvidaClaire M GulmiClaire M GulmiBoard Member · Community Healthcare TrustMatthew WalkerMatthew WalkerBoard Member · Solarea BioGlenn MattesGlenn MattesBoard Member · Viking Scientific